Bacterial and Host Determinants of Cough Aerosol Culture Positivity in Patients with Drug-resistant Versus Drug-susceptible Tuberculosis
Overview
Molecular Biology
Authors
Affiliations
A burgeoning epidemic of drug-resistant tuberculosis (TB) threatens to derail global control efforts. Although the mechanisms remain poorly clarified, drug-resistant strains are widely believed to be less infectious than drug-susceptible strains. Consequently, we hypothesized that lower proportions of patients with drug-resistant TB would have culturable Mycobacterium tuberculosis from respirable, cough-generated aerosols compared to patients with drug-susceptible TB, and that multiple factors, including mycobacterial genomic variation, would predict culturable cough aerosol production. We enumerated the colony forming units in aerosols (≤10 µm) from 452 patients with TB (227 with drug resistance), compared clinical characteristics, and performed mycobacterial whole-genome sequencing, dormancy phenotyping and drug-susceptibility analyses on M. tuberculosis from sputum. After considering treatment duration, we found that almost half of the patients with drug-resistant TB were cough aerosol culture-positive. Surprisingly, neither mycobacterial genomic variants, lineage, nor dormancy status predicted cough aerosol culture positivity. However, mycobacterial sputum bacillary load and clinical characteristics, including a lower symptom score and stronger cough, were strongly predictive, thereby supporting targeted transmission-limiting interventions. Effective treatment largely abrogated cough aerosol culture positivity; however, this was not always rapid. These data question current paradigms, inform public health strategies and suggest the need to redirect TB transmission-associated research efforts toward host-pathogen interactions.
Njagi L, Tram K, Zifodya J, Paul S, Ross J, Murithi W Open Forum Infect Dis. 2025; 12(3):ofaf077.
PMID: 40046891 PMC: 11880886. DOI: 10.1093/ofid/ofaf077.
Viewpoint on WHO implementation guidance on tuberculosis infection prevention and control.
Akkerman O, Migliori G, Falzon D, Garcia-Basteiro A, Kanchar A, Konstantynovska O Eur Respir J. 2024; 64(6).
PMID: 39542460 PMC: 11635381. DOI: 10.1183/13993003.00109-2024.
Nathavitharana R, Pearl A, Biewer A, Young L, Mukasa L, Delrooz N Clin Infect Dis. 2024; 80(1):189-198.
PMID: 39401315 PMC: 11797387. DOI: 10.1093/cid/ciae496.
Community-Wide Active Case Finding for Tuberculosis: Time to Use the Evidence We Have.
Coleman M, Lowbridge C, du Cros P, Marais B Trop Med Infect Dis. 2024; 9(9).
PMID: 39330903 PMC: 11436250. DOI: 10.3390/tropicalmed9090214.
Nduba V, Njagi L, Murithi W, Mwongera Z, Byers J, Logioia G Nat Commun. 2024; 15(1):7604.
PMID: 39217183 PMC: 11365933. DOI: 10.1038/s41467-024-52122-x.